Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Baker Heart and Diabetes Institute wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Coronary artery disease wikipedia , lookup
Echocardiography wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Saturated fat and cardiovascular disease wikipedia , lookup
Prognostic value of CA 125 in mild to moderate heart failure patients E Vizzardi1, N Pezzali1, A. D’Aloia1, G.Faden1, M Metra1, L Dei Cas1 1Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University and Hospital Brescia, Italy Purpose • • • Plasma levels of tumoral carbohydrate 125 antigen marker (CA 125) have been found elevated among patients (pts) with heart failure (HF). They relate to clinical condition and to diastolic and systolic left ventricle(LV) parameters, as previously observed. Also, CA125 has already been found to independently be related to mortality among acute and advanced HF pts. Results •During the follow-up, 16 (15.68%) cardiovascular deaths and 23 (22.54%) cardiovascular deaths+hospitalizations occurred. •15 (14.7%) pts showed CA125 levels >30 U/ml (established cut-off value). •Considering cardiac death, comparison of Kaplan Meyer survival curves by the logrank test showed We evaluated the prognostic value of CA125 in a population of pts with mild to moderate HF. that: • pts with CA125 levels higher than the cut-off value had a worse survival vs the others (p<0.0001, Methods Serum levels of CA 125 were obtained in 102 pts with mild to moderate HF due to idiopathic (48%) or ischemic (52%) dilated cardiomyopathy (age 64+10.6 years left ventricular ejection fraction (LVEF), 34.36 + 8.54%, NYHA class 2+0.3,) under optimized medical therapy according to the guidelines (ACE inhibitors-ARBs 95 %, BB 86%). All the pts underwent a complete clinical examination and transthoracic echocardiography. Events occurring in a mean 1380.4±487.5 days follow-up were recorded. HR 0.01722 among pts with CA125 levels lower than the cut-off value, 95% CI 0.003173-0.09344). •This was observed also when considering cardiovascular death+hospitalizations as the end-point (p=0.0003, HR 0.07248 among the pts with CA125 lower than the cut-off value, 95% CI 0.017230.3049). •Moreover, pts with CA125 levels equal or higher than 75% percentile showed a worse survival vs the other quartiles groups, with a higher incidence of cardiac deaths as well as cardiovascular death+hospitalizations (p<0.0001). Conclusions: In mild-to-moderate HF pts under optimized therapy, higher plasma CA 125 levels are an effective prognostic marker in forecasting cardiovascular events and hospitalization and may contribute to a better risk stratification.